OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma
Roberto Contieri, Alberto Martini, Laura S. Mertens, et al.
European Urology Focus (2024) Vol. 10, Iss. 4, pp. 662-665
Closed Access | Times Cited: 11
Roberto Contieri, Alberto Martini, Laura S. Mertens, et al.
European Urology Focus (2024) Vol. 10, Iss. 4, pp. 662-665
Closed Access | Times Cited: 11
Showing 11 citing articles:
The Financial Burden of Localized and Metastatic Bladder Cancer
Pietro Scilipoti, Marco Moschini, Roger Li, et al.
European Urology (2024)
Closed Access | Times Cited: 7
Pietro Scilipoti, Marco Moschini, Roger Li, et al.
European Urology (2024)
Closed Access | Times Cited: 7
Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Francesca Zacchi, Anna Sordo, Irene Torresan, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Francesca Zacchi, Anna Sordo, Irene Torresan, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives
Mattia Longoni, Pietro Scilipoti, Francesco Soria, et al.
European Urology Oncology (2025)
Closed Access
Mattia Longoni, Pietro Scilipoti, Francesco Soria, et al.
European Urology Oncology (2025)
Closed Access
Urine‐Stable Aptamer‐Conjugated Gold Nanorods for the Early Detection of High‐Grade Bladder Cancer Residual Disease
Chiara Venegoni, Silvia Tortorella, Alessandra Caliendo, et al.
Advanced Healthcare Materials (2025)
Open Access
Chiara Venegoni, Silvia Tortorella, Alessandra Caliendo, et al.
Advanced Healthcare Materials (2025)
Open Access
Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer—A Systematic Review of the Current Status
Stacy R. Bedore, Joshua van der Eerden, Faizan Boghani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 9899-9899
Open Access | Times Cited: 2
Stacy R. Bedore, Joshua van der Eerden, Faizan Boghani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 9899-9899
Open Access | Times Cited: 2
Reducing financial toxicity in bladder cancer care
Jeremy Kurnot, Deborah R. Kaye
Current Opinion in Urology (2024) Vol. 34, Iss. 6, pp. 484-488
Closed Access | Times Cited: 1
Jeremy Kurnot, Deborah R. Kaye
Current Opinion in Urology (2024) Vol. 34, Iss. 6, pp. 484-488
Closed Access | Times Cited: 1
Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis
Yang Zhao, Xiaoqing Xu, Yuhan Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Yang Zhao, Xiaoqing Xu, Yuhan Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39
Constantin Rieger, Jörg Schlüchtermann, Michaela Lehmann, et al.
European Urology Oncology (2024)
Open Access | Times Cited: 1
Constantin Rieger, Jörg Schlüchtermann, Michaela Lehmann, et al.
European Urology Oncology (2024)
Open Access | Times Cited: 1
Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
Liyu Yang, Jian‐Ri Li, Chuan-Shu Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Liyu Yang, Jian‐Ri Li, Chuan-Shu Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States
Guiyuan Xiang, Yue-Yue Huang, Lanlan Gan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Guiyuan Xiang, Yue-Yue Huang, Lanlan Gan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China
Kehui Meng, Heng Xiang, Mei-Yu Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Kehui Meng, Heng Xiang, Mei-Yu Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
Pietro Scilipoti, Marco Moschini, Alberto Briganti
Cell Reports Medicine (2024) Vol. 5, Iss. 12, pp. 101873-101873
Open Access
Pietro Scilipoti, Marco Moschini, Alberto Briganti
Cell Reports Medicine (2024) Vol. 5, Iss. 12, pp. 101873-101873
Open Access
